Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 5Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

Fulvestrant 65Letrozole 55Paclitaxel 54pembrolizumab 42Trastuzumab 42ribociclib 39Specimen Handling 36palbociclib 35Capecitabine 35Carboplatin 34Anastrozole 34Tamoxifen 32exemestane 31abemaciclib 31pertuzumab 29Cyclophosphamide 27Magnetic Resonance Spectroscopy 26trastuzumab deruxtecan 24Radiotherapy 22Surveys and Questionnaires 20Blood Specimen Collection 20olaparib 18Biopsy 18Standard of Care 17Docetaxel 17Taxes 15130-nm albumin-bound paclitaxel 15eribulin 14Methods 14Mastectomy, Segmental 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Breast Neoplasms × Imlunestrant × 90 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07287098 2026-05-22

preEMBER

Eli Lilly and Company

Phase 2 Not yet recruiting
600 enrolled
Breast

Breast Neoplasms

NCT05307705 2026-04-20

PIKASSO-01

Eli Lilly and Company

Phase 1 Active not recruiting
193 enrolled
Breast

Breast Neoplasms

NCT05509790 2026-04-13

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Eli Lilly and Company

Phase 1 Active not recruiting
17 enrolled
Breast

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

Eli Lilly and Company

Phase 3 Active not recruiting
8,000 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡